Information for Scientific Collaborators

	Research Collaboration: Procedures and Guidelines
	Orientation Document (study design, data collection, future data analysis, publications)
	Full Text of Questionnaires
	Phase 1 User Manual
	Phase 2 User Manual
	General File User Manual
	Resolved Reproductive Variables User Manual
	Data File Requests
	Advisory Panel Members
	Overview of Agricultural Health Study Data
	Usage Notes Pertaining to P1-P2 Analysis File

Cancer incidence and mortality data on the cohort are being obtained from cancer registries within Iowa and North Carolina and state vital statistics offices on a yearly basis. In addition, mortality data on the cohort is being obtained every other year from the National Death Index (NDI). Cancer incidence in the cohort is presented in Table 2 and mortality in the cohort is presented in Tables 3.

Table 2a: Post-enrollment (Incident only) Malignant Cancer Cases by Site and Phase II Data Collection progress ^1,2,3

Incident Cases Only

Cancer Site	Total with Cancer	Completed Phase II	Returned Buccal Sample	Returned DHQ
Bladder	267	177	116	115
Brain	87	36	24	25
Breast	842	649	450	468
Bronchus and Lung	657	322	172	179
Colon	570	367	232	226
Head and Neck	67	35	20	17
Kidney and Renal Pelvis	220	123	84	83
Leukemia	191	109	75	64
Liver and Intrahepatic Bile Ducts	52	22	8	11
Melanoma	302	214	133	136
Mesothelioma	17	4	3	1
Multiple Myeloma	100	66	44	48
NHL	311	194	163	128
Oral	122	89	61	59
Ovary	79	59	33	35
Pancreas	130	67	28	33
Prostate	1,852	1,309	1,205	826
Rectum and Rectosigmoid Junction	230	148	88	94
Stomach	88	54	41	37
Thyroid Gland	101	68	45	43
Uterine	181	130	82	91
Other	525	313	184	191
Total	6,991	4,555	3,291	2,910

Table 2b: Pre- and Post-enrollment (Prevalent and Incident) Malignant Cancer Cases by Site and Phase II Data Collection progress ^1,2,3

Prevalent Plus Incident Cases

Cancer Site	Total with Cancer	Completed Phase II	Returned Buccal Sample	Returned DHQ
Bladder	349	225	147	142
Brain	106	48	31	32
Breast	1,297	992	682	720
Bronchus and Lung	702	340	182	191
Colon	714	453	297	284
Head and Neck	85	45	27	24
Kidney and Renal Pelvis	259	147	100	96
Leukemia	246	143	96	88
Liver and Intrahepatic Bile Ducts	54	23	9	12
Melanoma	430	306	189	198
Mesothelioma	17	4	3	1
Multiple Myeloma	111	70	48	51
NHL	414	253	203	174
Oral	178	126	86	86
Ovary	128	96	61	61
Pancreas	140	69	28	34
Prostate	2,280	1,581	1,371	1,022
Rectum and Rectosigmoid Junction	315	200	128	132
Stomach	95	56	42	38
Thyroid Gland	196	145	97	95
Uterine	273	198	121	139
Other	702	429	253	264
Total	9,091	5,949	4,201	3,884

¹ Cancer counts are based on nearly complete registry data through 2006.
² Subjects previously diagnosed with cancer at a different site are included.
³ Buccal cell receipts represent progress through 2009.
⁴ The 'Other' category includes in-situ bladder cancers.
⁵ SEER Site Recode ICD-O-3 (1/27/2003) Definition used for classifying cancers.

Table 3: Cause Specific Mortality of AHS Cohort, 1994-2007

Cause	Frequency	Percent	Cumulative Frequency	Cumulative Percent
Accidents	413	6.430	413	6.43
Cancer	2,334	36.36	2,747	42.49
Cerebrovascular Disease	341	5.31	3,088	48.11
Diabetes Mellitus	140	2.18	3,228	50.29
Heart Disease	1,835	28.59	5,063	78.88
Respiratory Disease	440	6.85	5,503	85.73
Other	916	14.27	6,419	100.00

Table 4: Medical Conditions ¹ (fully expanded accessible table)

	Private Applicators	Spouses	Commercial Applicators	Total
Number in Cohort:	N=52,394	N=32,346	N=4,916	N=89,656
Category	Count	Count	Count
Completed Phase II Questionnaire	33,457	23,796	2,885	60,138
Cardiovascular Disease    Heart Attack (Myocardial Infarction) 1,789 370 122 2,281    Irregular Heart Beat (Arrhythmia) 3,267 2,571 243 6,081    High Blood Pressure or Hypertension 8,637 5,954 870 15,461
Endocrine Disorder    Diabetes or High Blood Sugar 2,429 1,314 188 3,931    Thyroid Disease or Thyroid Problems 1,075 2,947 90 4,112    Overactive Thyroid (Hyperthyroidism) 279 659 N/A 4 N/A    Graves Disease 62 151 N/A 4 N/A    Underactive Thyroid (Hypothyroidism) 528 1,792 55 2,375    Thyroiditis, Hashimoto's Disease, Autoimmune Disease 31 212 N/A 4 N/A    Enlarged Thyroid, Thyroid Nodules, Goiter 204 997 N/A 4 N/A    Other Thyroid Problem 113 169 N/A 4 N/A
Women's Health Disorder      Endometriosis N/A 2 1,694 N/A 2 N/A    Uterine Fibroids N/A 2 3,514 N/A 2 N/A    Benign Breast Disease (Fibroids, Cysts, Other) N/A 2 4,060 N/A 2 N/A    Pregnancy Induced High Blood Pressure,    Pre-Eclampsia, Toxemia or Eclampsia N/A 2 103 N/A 2 N/A    Gestational Diabetes N/A 2 77 N/A 2 N/A
Autoimmune/Musculoskeletal Disorders    Rheumotoid Arthritis N/A 2 908 N/A 2 N/A    Lupus (SLE) N/A 2 110 N/A 2 N/A    Sjogren's Disease N/A 2 43 N/A 2 N/A    Scleroderma or Systemic Sclerosis N/A 2 32 N/A 2 N/A
Kidney Disorder    Kidney Stones 3,862 1,279 200 5,341    Kidney Disease or Kidney Failure 354 214 28 596
Digestive Disorder    Inflammatory Bowel Disease    (Chron's Disease, Ulcerative Colitis) 430 514 41 985
Skin Disorder    Vitiligo 130 84 N/A 4 N/A    Eczema 719 1,124 89 1,932    Psoriasis 821 582 76 1,479    Allergy to Bees, Wasps, or Other Insects 1,735 1,120 158 3,013
Optical or Hearing Disorder    Blindness 619 N/A 3 36 N/A    Nearsightedness 12,237 N/A 3 1,345 N/A    Farsightedness 13,683 N/A 3 1,217 N/A    Cataracts 3,427 N/A 3 199 N/A    Glaucoma 680 N/A 3 49 N/A    Detached Retina 358 N/A 3 30 N/A    Retinal or Macular Degeneration 391 N/A 3 34 N/A    Hearing Problems 11,781 N/A 3 913 N/A
Injury    Head Injury 6,623 1,556 726 8,905    Neck, Back, Spinal Cord Injury 6,250 2,198 588 9,036    Post-Polio Syndrome, Leg Injury 4,344 1,474 188 6,006
Neurologic Disorder    Epilepsy 123 127 N/A 4 N/A    Multiple Sclerosis 39 83 N/A 4 N/A    Parkinson's Disease 89 29 N/A 4 N/A    Tremor (Essential, Familial, Benign) 144 113 N/A 4 N/A

¹ Numbers represent medical conditions reported during Phase II interviews. Because the asking of some questions was dependent on responses to earlier questions, the counts in this table reflect the numbers of each condition reported but not the total occurrence of the diseases in the cohort.
² These conditions marked with N/A were not asked about in the men's health questions. Since 96 percent of private applicators and commercial applicators in the cohort are men, it would be misleading to report counts for these conditions in the private applicator column.
³ Hearing problems were not asked about in the women's health questions. Since 99.5 percent of spouses in the cohort are women, it would be misleading to report hearing problem counts in the spouse column.
⁴ These conditions occur in commercial applicators in insufficient numbers to be reported at this time.